CDK4/6 Inhibitors in Cancer: Interactive Challenge

PROGRAM DESCRIPTION Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and ...

PROGRAM DESCRIPTION
Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way.In the format of an entertaining (but challenging!) interactive game, this edition of Scale, Bail or Fail presents and discusses the latest updates on CDK4/6 inhibition research and its clinical implications. This activity also features downloadable resources (including supplemental figures and tables).

EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be able to:Explain the mechanism of action of CDK4/6 inhibitorsEvaluate safety and efficacy data on the use of CDK4/6 inhibitors for solid tumors and their potential implications for clinical practice

---

Write the first review

Resource tags